Assessment of potential mutagenic activities of a novel benzothiazole MAO-A inhibitor E2011 using Salmonella typhimurium YG1029.
The potential initiation activities of a novel monoamine oxidase type-A (MAO-A) inhibitor E2011, which induced preneoplastic foci in the rat liver, were investigated by comparing the mutagenic activity of E2011, 6-aminobenzothiazole (6-ABT, a structural scaffold of E2011) and its derivatives, which are suggested primary reactive metabolites for E2011-induced hepatotoxicity in the rats in vivo, in the Ames assay system employing two Salmonella tester strains, TA100 and YG1029, a bacterial O-acetyltransferase-overproducing strain of TA100. E2011, a tertiary amine, showed no mutagenic activity both in the Salmonella typhimurium TA100 and YG1029 with and without S9 mix. On the other hand, a secondary aromatic amine ER-174238-00, a typical decarbonated metabolite of E2011, showed weak but significant mutagenicity in YG1029 in the presence of S9 mix, and a primary aromatic amine ER-174237-00, an N-dealkylated derivative of ER-174238-00, exhibited S9-dependent potent mutagenicity in YG1029. Thus, it appears that primary and secondary amino moieties of benzothiazole derivatives at C(6)-position are the specific structures contributing to their mutagenic activity. In addition, the alkyl group at C(2)-position of E2011, ER-174237-00 and ER-174238-00 is suggested to intensify the mutagenic activity, since the mutagenicity of ER-174237-00 is approximately two-fold higher than that of 6-ABT, which has hydrogen at C(2)-position in the place of the alkyl group. These results strongly suggest that E2011 has potential initiation activities in the rat liver in vivo after undergoing decarbonation, one of the metabolic pathways, at the carbonyl moiety of oxazolidinone ring to form mutagenic amine(s).
Sato
G
G
Exploratory Safety Assessment Research, Eisai Co. Ltd., 300-2635, Ibaraki, Japan. g-sato@hhc.eisai.co.jp
Asakura
S
S
Hakura
A
A
Tsutsui-Hiyoshi
Y
Y
Kobayashi
N
N
Tsukidate
K
K
D000123:Acetyltransferases / Q000378:metabolism; D000818:Animals; D052160:Benzothiazoles; D001711:Biotransformation; D002273:Carcinogens; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008113:Liver Neoplasms / Q000139:chemically induced; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D009152:Mutagenicity Tests; D009153:Mutagens / Q000494:pharmacology*; D023303:Oxazolidinones / Q000494:pharmacology* / Q000633:toxicity; D011230:Precancerous Conditions / Q000139:chemically induced; D051381:Rats; D012486:Salmonella typhimurium / Q000187:drug effects* / Q000235:genetics; D013329:Structure-Activity Relationship; D013844:Thiazoles / Q000494:pharmacology* / Q000633:toxicity
D052160:Benzothiazoles; D002273:Carcinogens; C091708:E 2011; D008996:Monoamine Oxidase Inhibitors; D009153:Mutagens; D023303:Oxazolidinones; D013844:Thiazoles; D000123:Acetyltransferases; C005465:benzothiazole